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59 ~ 11 years (69% mates). History of prevmus MI was present in 4b% el 
the I:)ts and 13% presented with cardtogenic shock, The culpnt lesion was 
located in tha LAD (23%), RCA (37%), LCX (11%) or a ~apbenous vein graft 
(28%), Adjunhv~ pereutaneou~ mvasculanzation wag I~rtormed tn 93% of 
the I~t~ents; PTCA alone (46%), coronary stentmg (46%), and rotational 
athemctomy (1%) Pemont dmmeter stenosm was reduced from 82% to 50% 
after Anglolet. and to 2_4% after (f~finitM~ treatment (P = 0,0001 ), 
Procedural SuccesS. defined as the esto~ti0n of TIMI 3 flow and m. 
hO~l~l ~ froth (~41th, eff~flf]6ftf bY~ISS §urg~ry or malor d~saJ~ling 
~tf¢~ke, wSS ~i~hed in g8%, Procedure compl~tmns included d~st~l 
~ lza l lon  (2%), translenl no.relfow (2%), and al~'upt Closure ( :~)  At 1 
Oir,¢al !~ UP, 2 (2%) pl~ cf;ed; 3 (3%) patients had recurrent Mt 
and 2_ (~'~) requtft~l mpe-~h~;I t~lOel vessel parcutaneous re~a~lanzation 
At ! month fcdlOw UP 82 (92%) pabents were stive and free from recurrent MI 
and repeat mvasO~anzaben pmOadum, 
Conctuszons: The Ar~,olet m a promising adtuntrve device for establishm 9
pateno/m t h ~  laden Les~.  !t t5 Of parlv~ula f utility if1 ~cute mvo¢ardlal 
mfarcl~n where the ~nce  Of coronary t~rom~ enhances the pa~prOco, 
dum C~tm~ rate. 
• !. Ipolomal POE-! Adjun~ive Treatment for 
Acute Myo¢a~ia l  In fa~l lon:  Final Resul ls  of  the 
UFT Pifot Trial 
RW, Srsalhng, R P Ka~rg .  R Wemer. DG Ebemote. U Thadam, 
E Bates, G.B Hal~b, D. ~k~hterno, YC Park J J Fre~ag For the LIFT 
~t~ja~rs ,  The Urm~=m;t), of Texas Med~'al ~ 1  and Hermann 
~ Ho~tOn. T~a.~ USA 
Backg~otmd ~ PGE-1 (TLC-C53) mhd~ted platelets and tCAM-1 
expmssmn which accelerated ~ombolysLS and reduced infarct size m an,real 
myocardial infambon models. 
A~thods: To evahJate the effect of TLC-C53. an mvest~ational drug, on 
mroml~ and infarct saNage, 121 pat~,nts wdh myocardial Infarction (MI) 
were random~ed to ~ edher TLC-C.53 (bohn, plus 5 add~onal closest48 
hours) or' idacebo lust prior tO trot'if-loaded t-PA Coronary ~ was 
performed at 30, 60 and 90 mmufes and 5-7 days after admission. Leh 
ventncuk~ was pertom'ted acutely and 5-7 days po~ Mr. Ang;ograms 
were analyzed for TIMI flow. oJo4~l and ~ I  left ventncutar func~an 
Resu~s: Patents were well matched for age. weh~ and time to treatntent 
There was a trend toward better eady T1MI 3 patency in the TLC.C53 patients 
at 60 minutes post treatment (53 vs 47%. p = N$) However. at 90 n',nutes 
the T1MI 3 patency was equwa~ent (54 vs 55%). There was also a trer~l 
toward lower remtamtmn and re-oo:lus~n rn the TLC-C53 group compared 
to placebo (2 v5 11% respeclwely; p = 006) There were no ~ferences =n 
acute or folfow-up ejection fractmn or regional km.c~on between the groups 
Conctus~" TLC-C53 chd not produce drama~c ~mprovements m ~nfarcl 
sah~age o~ vessel patency at the dosage level and frequency evaluated 
however ~t may reduce recurrent tschen.a and re~ntaret~on 
I 116%152t  Phase I Safety Trial of Soluble Complement  
Receptor Type I (TP 10) in Acute Myocardial  
Infarct ion 
GJ. Pe~ry. PR  E|senberg. J L  Zimmerman. J Lewn Bfrrnmgham Veterans 
AcMu.'~strat;o.'~ Medical Center. Bzrm~ngt~m AL. T Cell Soences. Needham. 
MA. USA 
Background: Complement actwatmn occurs v~ acute MI and may contnbute to 
ropeduslon in|u~. Thus complement inhtb~bon m~ght reduce mlury tollowng 
PTCA or thrombolysts for MI. Th~s phase I trial tested the pharmacok~netics 
(PK) and safety ot the complement inhibitor TP t O (1" Ceil Sc~encos, Needham. 
MA). a recombinant soluble form of human e~'th=ocyte complement receptor 
1 
Methods: TP10 was given by open label, ascending dose schedule (01, 
0.3. 1.3. or 10 mg/kg Lv. over 30 rain.) to 24 patrents re:eiwng lytics (n = 9) 
or pnma~y PTCA (n = 15) for first MI. CHS0, C3a, and C4a were measured 
at 0. 8, 24.48. and 168 hr. 
Results: There were no immunogemc responses or senous adverse ef- 
fects directly attnbuted to TP10. Non-compartmental PK analysis showed 
TP10 h,~ = 94.5 ± 57.5 hr. TPtO caused dose (p • 0.05 for 0.1 vs higher 
doses) and time-dependent (p < 0.(}5 for 8 and 24 hr vs O and 168 hr) de- 
crease o! CH50 (2 way ANOVA). C3a tended to fall at 8 h relative to 0 h (p 
= ns] at all TP10 doses, in contrast to the predicted nse with MI. suggesting 
complement inhibition. As expected based on the mechanism of action of 
TP10, there was no time or dose effect on C4a. In patients receiving lyrics 
there was a trend toward lower CKMB (normalized to ECG area at risk) in 
those receiving higher ( > 1.0 mg/kg) vs lower dose TP10 (52 vs 511. p = 0.06). 
Conclusion: TP10 is well tolerated and non-immunogenic in ML The 
expected rise in C3a during MI was not seen at any dose of TP 10. suggesting 
effective complement suppression in these patients. 
I 1161-1 53 } A K*-ATP Channel Opener. Nl¢ofandl;. Bruited 
Imar¢t Size In Psttents With A=ut~ Myo¢a~llal 
InMrcflon 
Y Sakata. K. Kodama, A. Hitayama. M. Kitaka~.."e, M. Hoe. O~aka PeAce 
HOs~al, Osaka; ~ U ~ ,  S~4a, JN~O 
Background: We have moe~t~t repotted tt~t ft~Oflff~l (NCR), a K'.ATP 
channel ol~ner , restori~ blood flow tO ~ ~ myocard~um patlem~ 
(pt~) wllll acuto myoc~rd~! Infafcllon (AMI), ~ , i t  ~ ur4mown 
the mf~r~t s~'e,ltmfling effe~-I of NCR, Thus we SOg~ tO ~wel~ate 
NCR tirol infarct s~ in I~  ~ th~f fI~!t Nl~mof AML 
Me~O~: Alter {zu¢~sful comnap/inflow, !S !~ ~ ~ W  
ad~,mstmhen of NCfl (2 rag), and 18 pts moeNed plar..eoo, Pe~ mm~n 
c~atlne ktn.~-e (CK) levels, defect vek~me m(l~w (DvI) O~em,ned by ma~ 
hum.,~01 ~,PECT, g ro~ ~ ~ (E~ aed left ~mt~ 
foim volume inde~ (EDVI) in the ~uto stage and one_ month a f t '  the 
were congsamd between the two ~ o1 patmm1~, 
Resu,ls: !) Thee were no differef~es between the two gmupa m age, 
gender and t~me to repartus~,n (4.2 ~: 2`2 VS 4.6 ± 1,6 hm, p = O.e4). 2) Peak 
CK (2248 ± 1386 vs 3642 ~ 1624 U/L p = 0.03) and peak CK-MB (191 ± 
119 VS 303 ± 122 U/L, P = 0.03) leve~s'~i~e s~mflcanfty lower m NCR group. 
3) DVI was s~gnd]cantly lower in NCR group (961 ± 735 v~ 1557 ± 781 U, 
p = 005) 4) EF was s~t~, i ;y  m~pmved m a month In NCR group (42 ± 
14 to 52 ± 16%. p = 0.03), while ~I was not m placebo group (44 ± 11 1047 
13%, p = 026). 5) EDVI d~d not differ bolh at the a~de stage and a month 
alter the onset. 
~ :  fotraco~na~/~.qmi,aiK:m of NCR limd~l inMrct size and 
• nlp¢oved flmclional ~ in a m~nl~ aftra, the onlof. T h u s ~  
nv:orancbt aa~n~stra~ seems to be a useful adiunctn~ therapy follow~g 
~uccess~Jt coronary repertusmn m patmnts w~th AMI. 
Diagnost ic  Methods of ~ i n g  Ischemia 
Wednesday, April 1, 1998, 9;O0 a .m.-11:00 a,m, 
Georg ia  Wor ld  Congress Center,  West  Exhibit Hall Level  
P resentat ion  Hour:. 10:00 a .m. -11 :00  a.m. 
I 1162-131J  Beneficial Effects of  Tmglitazone in Vuospast i¢  
Angina Peetods With Diabetes Mellitus 
T Murakams, Y AmL B. Kaku. Fukui CaK1mvascular Center, Fukua, Japan 
BackgrounO~: The retahonshlps between msuhn resistance and coronary 
affe~ ( ~  have a great deal of affentmn. 
P .~:  In order to investigate wheffmr t~gfrtazone, recently used for m~ 
suitn resistance, has t rac ts  upon clinical manlt'eslations of corenary a f t i~  
~.ease we adm~mstered troglffazone for tour months in diabetic patients 
wm~ ar~ographlcally decumenmd co~nary vasospasm and resm~ual ngina 
pec~or~ even ~ commnl~al me~lK)ns for vasospaztic angina peclons 
(n = 8) At base,me and at four months after medica l ,  we assessed a~gt- 
nal e ~  and non.~nvas~,ely measured the macth~e changes m lumen 
diameter of right brachlal artery folfowmg transient ocdu~uon four five mmutos 
(FMD; flow-nle~ated @hum-dep~- ,G~sl  vasodilatlon), and affe¢ sublm. 
gual admlmstra~on of (300 .g) glycenl tnnrlrate (GTN; endotbelium-ind~.~- 
dent vasod~latren). 
ResuRs: Dur;,tmn of anginal epmodes (AP; minutes per month) were 
s~T,f¢an~ redt~-ed after med¢atren. FMD was improved after medtcatmn, 
GTN was sit.tar oefore and after meo~cahon Reductmn of AP was coffelMed 
to rn~rovement of FMD (r = 06. p < 001). 
groined;cat,on poslmeOtc-af~on p valuo 
AP 72 :. 68 14 ~- 17 004 
FMD 43~ 14% 66= 16% 003 
GTN 11 5 ~43% 133 ~: 29% ns 
Conctusrons: These findings suggest that lroglitazone improves endothe- 
hum-dependent vasomactw'~ms and reduces anginal episodes in diabetic 
patients w~th vasos~asbc angina pecfons, and insulin-resistance may con. 
tnbute to clinical manifestation el vasospashc angina pacfons wdh diabetes 
meltitus. 
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